Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Stock Short Interest Drops 87.3%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a significant drop in short interest in the month of September. As of September 30th, there was short interest totaling 56,158 shares, a drop of 87.3% from the September 15th total of 440,994 shares. Based on an average daily trading volume, of 119,021 shares, the short-interest ratio is currently 0.5 days. Currently, 6.0% of the company’s shares are short sold.

Matinas Biopharma Stock Performance

Shares of NYSEAMERICAN MTNB traded up $0.04 during trading on Friday, reaching $2.87. The stock had a trading volume of 35,267 shares, compared to its average volume of 142,341. The company has a market cap of $2.81 million, a P/E ratio of -0.16 and a beta of 2.08. Matinas Biopharma has a fifty-two week low of $2.26 and a fifty-two week high of $28.95. The business’s 50-day moving average price is $3.03 and its 200-day moving average price is $6.76.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its earnings results on Thursday, August 13th. The company reported ($3.15) earnings per share (EPS) for the quarter.

Matinas Biopharma Company Profile

Matinas BioPharma, Inc is a clinical-stage biotechnology company developing medicines based on its proprietary lipid nanocrystal (LNC) delivery technology. The platform is designed to improve the oral delivery of active pharmaceutical ingredients that may otherwise have limited absorption or require intravenous administration.

The company’s lead program, MAT2203, is an oral formulation of amphotericin B, an antifungal medicine traditionally administered intravenously. Matinas has studied MAT2203 for serious systemic fungal infections, including cryptococcal meningitis, and has evaluated its potential to provide an orally administered alternative with fewer administration-related burdens.